Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)

Stock Information for Athersys Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Athersys Inc.

Athersys to Host Third Quarter Financial Results Call
Athersys to Present at 2019 Cell & Gene Meeting on the Mesa
Athersys Reports Second Quarter 2019 Results
Athersys to Host Second Quarter Financial Results Call
Athersys to Present at Jefferies 2019 Healthcare Conference
Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference
Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference
Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.